Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2– Advanced Breast Cancer

Alpelisib and endocrine therapy provides ongoing treatment benefits for patients with HR-positive, HER2-negative, PIK3CA-mutated advanced breast cancer, according to updated findings from all 3 cohorts of the phase II BYLieve trial.

Detalles Bibliográficos
Autor principal: Jacobson, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Conference Perspectives: Highlights from SABCS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963159/
https://www.ncbi.nlm.nih.gov/pubmed/35348782
http://dx.doi.org/10.1093/oncolo/oyac011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963159/
https://www.ncbi.nlm.nih.gov/pubmed/35348782
http://dx.doi.org/10.1093/oncolo/oyac011

Ejemplares similares